Cadrenal Therapeutics starts strategic review

Cadrenal Therapeutics said its board authorized a formal strategic process to evaluate opportunities to maximize value of the company and its asset portfolio. Potential options include licensing or sale of individual assets, partnerships, portfolio transactions, business combinations or other strategic transactions.